content: <HTML>
  <HEAD>
       <TITLE></TITLE>
  </HEAD>
  <BODY STYLE="font: 10pt Times New Roman, Times, Serif">
  
  <P STYLE="margin: 0"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">As filed with the Securities and Exchange Commission on
  April 4, 2018&#9;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Registration No. 333-____</P>
  
  <!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNITED STATES</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">WASHINGTON, D.C. 20549</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center">_______________</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center">FORM S-8</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">REGISTRATION STATEMENT</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">UNDER</P>
  
  <P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center"><FONT STYLE="font-variant: normal">THE
  SECURITIES ACT OF 1933</FONT></P>
  
  <P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center"><FONT STYLE="font-variant: normal">_____________</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>WIZE PHARMA, INC.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">(Exact name of registrant as specified
  in its charter)</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 46%; padding-right: 5.4pt; padding-left: 5.4pt; border-bottom: Black 1pt solid"><P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-decoration: none; text-transform: none; text-align: center; vertical-align: baseline"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: baseline"><B>Delaware</B></FONT></P>
          <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 48.6pt 0 0; text-decoration: none; text-transform: none; text-align: center; vertical-align: baseline"></P></TD>
      <TD STYLE="width: 9%">&nbsp;</TD>
      <TD STYLE="width: 45%; padding-right: 5.4pt; padding-left: 5.4pt; font: bold 10pt Times New Roman, Times, Serif; text-decoration: none; text-transform: none; vertical-align: baseline; border-bottom: Black 1pt solid"><P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-decoration: none; text-transform: none; text-align: center; vertical-align: baseline"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: baseline"><B>88-0445167</B></FONT></P>
          <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.55in; text-align: center"></P></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(State or Other Jurisdiction of Incorporation
          or Organization)</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(I.R.S. Employer Identification Number)</TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><BR>
  <B></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>5b Hanagar Street, Hod Hasharon, Israel, 4527708</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Address of Principal Executive Offices; Zip
  Code)</P>
  
  <P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center"><FONT STYLE="font-variant: normal">_______________</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Wize Pharma, Inc. 2018 Stock Incentive Plan</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Full Title of the Plan)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center">_______________</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Or Eisenberg</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Acting CEO and CFO</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Wize Pharma, Inc.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>5b Hanagar Street</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Hod Hasharon, Israel</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>4527708</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Name and Address of Agent for Service)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>+972 (72) 260-0536</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Telephone Number, Including Area Code, of
  Agent for Service)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant
  is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth
  company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting
  company,&rdquo; and &quot;emerging growth company&quot; in Rule 12b-2 of the Exchange Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
      <TD STYLE="width: 40%">Large accelerated filer&nbsp;</TD>
      <TD STYLE="width: 2%">&nbsp;&#9744;</TD>
      <TD STYLE="width: 7%">&nbsp;</TD>
      <TD STYLE="width: 26%">Accelerated filer&nbsp;</TD>
      <TD STYLE="width: 25%">&nbsp;&#9744;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
      <TD>Non-accelerated filer</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>Smaller reporting company</TD>
      <TD>&nbsp;&#9746;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
      <TD>(Do not check if a smaller reporting
  company)</TD>
      <TD>&nbsp;&#9744;</TD>
      <TD>&nbsp;</TD>
      <TD></TD>
      <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>Emerging growth company</TD>
      <TD>&nbsp;&#9746;</TD></TR>
  </TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If an emerging growth company, indicate by
  check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
  accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act<FONT STYLE="font-size: 10pt">. &#9746;</FONT></P>
  
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>
  
  <!-- Field: Page; Sequence: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CALCULATION OF REGISTRATION FEE</B></P>
  
  <P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1.5pt solid">Title of Each Class of Securities to be Registered</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Amount</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>to be Registered (1)</B></P></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Proposed Maximum Offering Price Per Share (2)</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Proposed Maximum Aggregate Offering Price (2)</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount of Registration Fee (3)</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="width: 52%; font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0.1in">Common Stock, $0.001 par value</TD><TD STYLE="width: 1%; font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
      <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">435,052</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; font-variant: small-caps; padding-bottom: 1.5pt">&nbsp;</TD>
      <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; font-size: 10pt; font-variant: small-caps; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; font-size: 10pt; font-variant: small-caps; text-align: right">3.74</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; font-size: 10pt; font-variant: small-caps; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
      <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">1,627,094.48</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
      <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">202.57</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; font-size: 10pt; text-align: left">(4)</TD></TR>
  </TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in; text-align: justify">&nbsp;</P>
  
  <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">Pursuant
                                           to Rule 416(a) under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;),
                                           there are also being registered hereby an additional indeterminate number of shares of
                                           the Registrant&rsquo;s Common Stock, $0.001 par value (the &ldquo;Common Stock&rdquo;)
                                           as may become issuable to the selling stockholders as a result of stock splits, stock
                                           dividends and similar transactions, and, in any such event, the number of shares registered
                                           hereby shall be automatically increased to cover the additional share.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(2)</TD><TD STYLE="text-align: justify">The proposed
                                           maximum offering price per share and the proposed maximum aggregate offering price have
                                           been estimated solely for the purpose of calculating the amount of the registration fee
                                           in accordance with Rules 457(c) and 457(h) under the Securities Act, based on the average
                                           of the high and low closing prices of our Common Stock on April 3, 2018, as reported
                                           on the OTCQB, a date within five (5) business days prior to the date of this Registration
                                           Statement.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(3)</TD><TD STYLE="text-align: justify">Determined in accordance with Section 6(b) of the Securities Act at a rate
  equal to $124.50 per $1 million of the proposed maximum aggregate offering price.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(4)</TD><TD STYLE="text-align: justify">The Registration Fee is being offset against a portion of the fee paid by
  the Company upon the filing of a Registration Statement on Form S-1 on February 6, 2018, as a result of the Company&rsquo;s reverse
  stock split of its Common Stock at a ratio of one for twenty-four (1:24) which was effected on March 5, 2018.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">________________________________</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>This Registration Statement shall become effective immediately
  upon filing as provided in Rule 462 under the Securities Act of 1933.</B></P>
  
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"></P>
  
  <!-- Field: Page; Sequence: 2 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">EXPLANATORY NOTE</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">As used in this Registration Statement, the
  terms &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; the &ldquo;Company,&rdquo; &ldquo;Wize,&rdquo; &ldquo;our company&rdquo;
  and the &ldquo;Registrant&rdquo; refer to Wize Pharma, Inc. (formerly known as OphthaliX, Inc.), a Delaware corporation. The references
  to the &ldquo;Commission&rdquo; are to the United States Securities and Exchange Commission.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On February 22, 2018, the Board of Directors
  approved the adoption of the 2018 Stock Incentive Plan (the &ldquo;2018 Plan&rdquo;), including the total number of shares of Common
  Stock that may be subject to awards under the 2018 Plan (subject to appropriate adjustments in the case of stock splits, stock
  dividends and similar recapitalization events, the &quot; Reserved Pool&quot;). As of the date hereof, the Reserved Pool is 435,052
  shares of Common Stock.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The purpose of this Registration Statement on
  Form S-8 is to register 435,052 shares of Common Stock for issuance under the 2018 Plan, all of which are reserved for issuance
  under future stock options, shares of Common Stock, restricted stock and restricted stock units of our company.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">PART I</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">INFORMATION REQUIRED
  IN THE SECTION 10(a) PROSPECTUS</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><B>Item 1. Plan Information.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">The Company will provide
  each recipient (the &ldquo;Recipients&rdquo;) of a grant under the 2018 Plan with documents that contain information related to
  the Plan, and other information including, but not limited to, the disclosure required by Item 1 of Form S-8, which information
  is not required to be and is not being filed as a part of this Registration Statement or as prospectuses or prospectus supplements
  pursuant to Rule 424 under the Securities Act. The foregoing information and the documents incorporated by reference in response
  to Item 3 of Part II of this Registration Statement, taken together, constitute a prospectus that meets the requirements of Section
  10(a) of the Securities Act. A Section 10(a) prospectus will be given to each Recipient who receives common stock covered by this
  Registration Statement, in accordance with Rule 428(b)(1) under the Securities Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><B>Item 2. Registrant Information and Employee
  Plan Annual Information.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">The Company will provide
  to each Recipient a written statement advising of the availability of documents incorporated by reference in Item 3 of Part II
  of this Registration Statement (which documents are incorporated by reference in this Section 10(a) prospectus) and of documents
  required to be delivered pursuant to Rule 428(b) under the Securities Act without charge and upon written or oral request by contacting:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">Or Eisenberg</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">Acting Chief Executive
  Officer and Chief Financial Officer</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">Wize Pharma, Inc.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">5b Hanagar Street</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">Hod Hasharon, Israel</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">4527708</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in; background-color: white">&nbsp;</P>
  
  <!-- Field: Page; Sequence: 3 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid; text-align: center">1</DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in; background-color: white"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">PART II</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">INFORMATION REQUIRED IN THE REGISTRATION
  STATEMENT</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">Item 3. Incorporation of Documents by Reference.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 42.55pt">Wize hereby incorporates by reference
  into this Registration Statement the following documents previously filed with the Commission:</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 23.25pt"></TD><TD STYLE="width: 21.75pt">(a)</TD><TD>the Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2017, filed with the Commission on March
  29, 2018;</TD></TR></TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 23.25pt"></TD><TD STYLE="width: 21.75pt">(b)</TD><TD>The description of the Registrant&rsquo;s Common Stock incorporated herein by reference from the Company&rsquo;s Registration
  Statement on Form S-4 filed with the Commission on July 27, 2017, and amended on September 5, 2017, including any amendment or
  report filed for the purpose of updating such description; and</TD></TR></TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 23.4pt"></TD><TD STYLE="width: 23.4pt">(c)</TD><TD>all other reports filed by the Registrant pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended
  (the &ldquo;Exchange Act&rdquo;), since the end of the fiscal year covered by the documents referred to in clause (a) above.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: left; text-indent: 0.5in">All documents subsequently
  filed by us pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, and all Current Reports on Form 8-K submitted
  to the Commission subsequent to the date hereof, to the extent that such Reports indicate that information therein is incorporated
  by reference into the Registrant&rsquo;s Registration Statements on Form S-8, prior to the filing of a post-effective amendment
  which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be
  deemed to be incorporated by reference in this registration statement and to be part hereof from the date of filing of such documents.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 47.95pt">Any statement contained in a document
  incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this
  Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed
  to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall
  not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Item 4.&nbsp;&nbsp;&nbsp;Description of
  Securities</B>.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Not applicable.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Item 5.&nbsp;&nbsp;&nbsp;Interests of Named
  Experts and Counsel</B>.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Not applicable.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Item 6.&nbsp;&nbsp;&nbsp;Indemnification
  of Directors and Officers</B>.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 35.45pt">As a corporation incorporated in the State
  of Delaware, we are subject to the Delaware General Corporation Law (&ldquo;DGCL&rdquo;). Section&nbsp;102(b)(7) of the DGCL allows
  a corporation to provide in its certificate of incorporation that a director of the corporation will not be personally liable to
  the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except where the director
  breached the duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized
  the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal
  benefit. Our charter provides for this limitation of liability.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 35.45pt">&nbsp;</P>
  
  <!-- Field: Page; Sequence: 4 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid; text-align: center">2</DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 35.45pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 35.45pt">&nbsp;Section&nbsp;145 of the DGCL (&ldquo;Section
  145&rdquo;), provides, among other things, that a Delaware corporation may indemnify any person who was, is or is threatened to
  be made, party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative
  (other than an action by or in the right of such corporation), by reason of the fact that such person is or was an officer, director,
  employee or agent of such corporation or is or was serving at the request of such corporation as a director, officer, employee
  or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys&rsquo; fees), judgments,
  fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding,
  provided such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the corporation&rsquo;s
  best interests and, with respect to any criminal action or proceeding, had no reasonable cause to believe that his or her conduct
  was unlawful. A Delaware corporation may indemnify any persons who were or are a party to any threatened, pending or completed
  action or suit by or in the right of the corporation by reason of the fact that such person is or was a director, officer, employee
  or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys&rsquo; fees) actually and
  reasonably incurred by such person in connection with the defense or settlement of such action or suit, provided such person acted
  in good faith and in a manner he or she reasonably believed to be in or not opposed to the corporation&rsquo;s best interests,
  provided further that no indemnification is permitted without judicial approval if the officer, director, employee or agent is
  adjudged to be liable to the corporation. Where an officer or director is successful on the merits or otherwise in the defense
  of any action referred to above, the corporation must indemnify him or her against the expenses (including attorneys&rsquo; fees)
  which such officer or director has actually and reasonably incurred.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 35.45pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 35.45pt">Section&nbsp;145 further authorizes a corporation
  to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation
  or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or enterprise,
  against any liability asserted against such person and incurred by such person in any such capacity, or arising out of his or her
  status as such, whether or not the corporation would otherwise have the power to indemnify such person under Section&nbsp;145.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 35.45pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 35.45pt">Our charter and bylaws provide that we must
  indemnify and advance expenses to its directors and officers to the full extent authorized by the DGCL.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 35.45pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 35.45pt">We expect to maintain standard policies of
  insurance that provide coverage (1)&nbsp;to our directors and officers against loss arising from claims made by reason of breach
  of duty or other wrongful act as defined in the policy and (2)&nbsp;to us with respect to indemnification payments that we may
  make to such directors and officers.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 35.45pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 35.45pt">The indemnification rights set forth above
  shall not be exclusive of any other right which an indemnified person may have or hereafter acquire under any statute, any provision
  of our charter, bylaws, agreement, vote of stockholders or disinterested directors or otherwise. Notwithstanding the foregoing,
  we shall not be obligated to indemnify a director or officer in respect of a proceeding (or part thereof) instituted by such director
  or officer, unless such proceeding (or part thereof) has been authorized by our board of directors pursuant to the applicable procedure
  outlined in our bylaws.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 35.45pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 35.45pt">Section&nbsp;174 of the DGCL provides, among
  other things, that a director, who willfully or negligently approves of an unlawful payment of dividends or an unlawful stock purchase
  or redemption, may be held jointly and severally liable for such actions. A director who was either absent when the unlawful actions
  were approved or dissented at the time may avoid liability by causing his or her dissent to such actions to be entered in the books
  containing the minutes of the meetings of the board of directors at the time such action occurred or immediately after such absent
  director receives notice of the unlawful acts.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Item 7.&nbsp;&nbsp;&nbsp;Exemption from
  Registration Claimed</B>.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Not applicable.</P>
  
  <!-- Field: Page; Sequence: 5 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid; text-align: center">3</DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Item 8. Exhibits.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><FONT STYLE="font-weight: normal">The following exhibits
  are filed as part of this registration statement:</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>EXHIBIT INDEX</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid; vertical-align: top"><B>EXHIBIT NO.</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
      <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; text-align: left; vertical-align: top"><B>DESCRIPTION</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="width: 12%; font-size: 10pt; text-align: left; vertical-align: top">3.1</TD>
      <TD STYLE="text-align: left; width: 1%">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000107878212000959/f8k040512_ex3z1.htm" STYLE="-sec-extract: exhibit">Certificate of Incorporation (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the Commission on April 5, 2012)</A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">3.2</TD>
      <TD STYLE="text-align: left">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000107878213001371/f8k071813_ex3z1.htm" STYLE="-sec-extract: exhibit">Certificate of Amendment to Certificate of Incorporation (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the Commission on July 18, 2013)</A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">3.3</TD>
      <TD STYLE="text-align: left">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390017012449/f8k111517ex3-3_wizepharma.htm" STYLE="-sec-extract: exhibit">Certificate of Amendment to Certificate of Incorporation dated November 15, 2017 (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the Commission on November 21, 2017)</A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">3.4</TD>
      <TD STYLE="text-align: left">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390018002556/f8k030118ex3-1_wizepharma.htm" STYLE="-sec-extract: exhibit">Certificate of Amendment to Certificate of Incorporation dated March 1, 2018 (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the Commission on March 5, 2018)</A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">3.5</TD>
      <TD STYLE="text-align: left">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000107878213000919/f8k051013_ex3z1.htm" STYLE="-sec-extract: exhibit">Bylaws (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the Commission on May 10, 2013)</A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">4.1</TD>
      <TD STYLE="text-align: left">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390018001336/fs12018ex4-1_wizepharma.htm" STYLE="-sec-extract: exhibit">Specimen Common Stock Certificate (Incorporated by reference to Company&rsquo;s Registration Statement on Form S-1 filed with the Commission on February 6, 2018)</A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">4.2</TD>
      <TD STYLE="text-align: left">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390018002393/f8k022218ex10-1_wizepharma.htm" STYLE="-sec-extract: exhibit">Wize Pharma, Inc. 2018 Equity Incentive Plan (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the Commission on February 28, 2018)</A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">5.1</TD>
      <TD STYLE="text-align: left">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="fs80418ex5-1_wizepharma.htm">Opinion of Sichenzia Ross Ference Kesner LLP*</A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">23.1</TD>
      <TD STYLE="text-align: left">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="fs80418ex5-1_wizepharma.htm">Consent of Sichenzia Ross Ference Kesner LLP (contained in Exhibit 5.1)</A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">23.2</TD>
      <TD STYLE="text-align: left">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="fs80418ex23-2_wizepharma.htm">Consent of Fahn Kanne &amp; Co. Grant Thornton Israel*</A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">24.1</TD>
      <TD STYLE="text-align: left">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="fs80418ex23-2_wizepharma.htm">Powers of Attorney (included in the signature page to this Registration Statement)</A></TD></TR>
  </TABLE>
  
  
  <P STYLE="margin: 0">___________</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in">* Filed herewith.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
  </P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B></B></P>
  
  <!-- Field: Page; Sequence: 6 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid; text-align: center">4</DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Item 9. Undertakings.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The undersigned Registrant hereby undertakes:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(1)&nbsp;To file, during any period in which offers or sales are
  being made, a post-effective amendment to this Registration Statement:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">i.&nbsp;To include any prospectus required by
  section 10(a)(3) of the Securities Act of 1933;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">ii. To reflect in the prospectus any facts or
  events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which,
  individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding
  the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would
  not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be
  reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume
  and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the &ldquo;Calculation
  of Registration Fee&rdquo; table in the effective Registration Statement;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">iii.&nbsp;To include any material information
  with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such
  information in the Registration Statement;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>provided, however</I>, that paragraphs (1)(i)
  and (1)(ii) of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs
  is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or 15(d) of the Exchange
  Act that are incorporated by reference in the Registration Statement.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(2) That, for the purpose of determining any liability under the
  Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities
  offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(3)&nbsp;To remove from registration by means of a post-effective
  amendment any of the securities being registered which remain unsold at the termination of the offering.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(4)&nbsp;The undersigned Registrant hereby undertakes that, for
  purposes of determining any liability under the Securities Act, each filing of the registrant&rsquo;s annual report pursuant to
  Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan&rsquo;s annual report
  pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed
  to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time
  shall be deemed to be the initial bona fide offering thereof.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(5)&nbsp;Insofar as indemnification for liabilities arising under
  the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing
  provisions, or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification is against
  public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification
  against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling
  person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or
  controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel
  the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification
  by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><BR STYLE="clear: both">
  </P>
  
  <!-- Field: Page; Sequence: 7 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid; text-align: center">5</DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center">SIGNATURES</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">Pursuant to the
  requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all
  of the requirements for filing on Form S-8 and has duly caused this registration statement on Form S-8 to be signed on its behalf
  by the undersigned, thereunto duly authorized, in the City of Hod Hasharon, Israel, on the 4<SUP>th</SUP> day of April, 2018.</P>
  
  <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD COLSPAN="2"><B>WIZE PHARMA, INC.</B></TD></TR>
  <TR>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="width: 6%">By:&nbsp;</TD>
      <TD STYLE="vertical-align: top; width: 35%">/s/ Or Eisenberg</TD></TR>
  <TR>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD>Name:<BR>
  Title:</TD>
      <TD STYLE="vertical-align: top; border-top: #000000 1px solid">Or Eisenberg<BR>Acting Chief Executive Officer, Chief&nbsp;Financial&nbsp;Officer, Treasurer and&nbsp;Secretary</TD></TR>
  </TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0in"><B><A NAME="poa"></A>POWER OF ATTORNEY</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Each of the undersigned officers and directors
  of Wize Pharma, Inc., a Delaware corporation, hereby constitutes and appoints Or Eisenberg and Noam Danenberg and each of them,
  severally, as his or her attorney-in-fact and agent, with full power of substitution and resubstitution, in his or her name and
  on his or her behalf, to sign in any and all capacities this registration statement and any and all amendments (including post-effective
  amendments) and exhibits to this registration statement and any and all applications and other documents relating thereto, with
  the Securities and Exchange Commission, with full power and authority to perform and do any and all acts and things whatsoever
  which any such attorney or substitute may deem necessary or advisable to be performed or done in connection with any or all of
  the above described matters, as fully as each of the undersigned could do if personally present and acting, hereby ratifying and
  approving all acts of any such attorney or substitute.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
  of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the
  dates indicated.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 180.6pt; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Signature</FONT></TD>
      <TD STYLE="width: 179.55pt; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Title</FONT></TD>
      <TD STYLE="width: 11.8pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
      <TD STYLE="width: 101.65pt; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Date</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
          <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
          <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">/s/ Or Eisenberg</P></TD>
      <TD ROWSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Acting Chief Executive Officer, Chief&nbsp;Financial&nbsp;Officer, Treasurer and&nbsp;Secretary</FONT></TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
      <TD ROWSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;April 4, 2018</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Or Eisenberg</FONT></TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
  <TR>
      <TD STYLE="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">/s/ Ron Mayron</FONT></TD>
      <TD ROWSPAN="3" STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">
          <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">Chairman of the Board</P>
          <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P></TD>
      <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
      <TD ROWSPAN="2" STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">April 4, 2018</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Ron Mayron</FONT></TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">/s/ Yossi Keret</FONT></TD>
      <TD ROWSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
      <TD ROWSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">April 4, 2018</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Yossi Keret</FONT></TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">/s/ Franck Amouyal</FONT></TD>
      <TD ROWSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Director </FONT></TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
      <TD ROWSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">April 4, 2018</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Franck Amouyal</FONT></TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
  <TR>
      <TD STYLE="vertical-align: bottom; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">/s/ Joseph Zarzewsky</FONT></TD>
      <TD ROWSPAN="2" STYLE="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Director </FONT></TD>
      <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
      <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">
          <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
          <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">April 4, 2018</P></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Joseph Zarzewsky</FONT></TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR>
      <TD STYLE="vertical-align: bottom; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
          <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
          <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">/s/ Michael Belkin</P></TD>
      <TD ROWSPAN="2" STYLE="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Director </FONT></TD>
      <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
      <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">
          <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
          <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
          <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">April 4, 2018</P></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Michael Belkin</FONT></TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>
  
  <!-- Field: Page; Sequence: 8 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid; text-align: center">6</DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>EXHIBIT INDEX</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid; vertical-align: top"><B>EXHIBIT NO.</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
      <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; text-align: left; vertical-align: top"><B>DESCRIPTION</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="width: 12%; font-size: 10pt; text-align: left; vertical-align: top">3.1</TD>
      <TD STYLE="text-align: left; width: 1%">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000107878212000959/f8k040512_ex3z1.htm" STYLE="-sec-extract: exhibit">Certificate of Incorporation (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the Commission on April 5, 2012)</A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">3.2</TD>
      <TD STYLE="text-align: left">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000107878213001371/f8k071813_ex3z1.htm" STYLE="-sec-extract: exhibit">Certificate of Amendment to Certificate of Incorporation (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the Commission on July 18, 2013)</A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">3.3</TD>
      <TD STYLE="text-align: left">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390017012449/f8k111517ex3-3_wizepharma.htm" STYLE="-sec-extract: exhibit">Certificate of Amendment to Certificate of Incorporation dated November 15, 2017 (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the Commission on November 21, 2017)</A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">3.4</TD>
      <TD STYLE="text-align: left">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390018002556/f8k030118ex3-1_wizepharma.htm" STYLE="-sec-extract: exhibit">Certificate of Amendment to Certificate of Incorporation dated March 1, 2018 (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the Commission on March 5, 2018)</A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">3.5</TD>
      <TD STYLE="text-align: left">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000107878213000919/f8k051013_ex3z1.htm" STYLE="-sec-extract: exhibit">Bylaws (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the Commission on May 10, 2013)</A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">4.1</TD>
      <TD STYLE="text-align: left">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390018001336/fs12018ex4-1_wizepharma.htm" STYLE="-sec-extract: exhibit">Specimen Common Stock Certificate (Incorporated by reference to Company&rsquo;s Registration Statement on Form S-1 filed with the Commission on February 6, 2018)</A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">4.2</TD>
      <TD STYLE="text-align: left">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390018002393/f8k022218ex10-1_wizepharma.htm" STYLE="-sec-extract: exhibit">Wize Pharma, Inc. 2018 Equity Incentive Plan (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the Commission on February 28, 2018)</A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">5.1</TD>
      <TD STYLE="text-align: left">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="fs80418ex5-1_wizepharma.htm">Opinion of Sichenzia Ross Ference Kesner LLP*</A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">23.1</TD>
      <TD STYLE="text-align: left">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="fs80418ex5-1_wizepharma.htm">Consent of Sichenzia Ross Ference Kesner LLP (contained in Exhibit 5.1)</A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">23.2</TD>
      <TD STYLE="text-align: left">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="fs80418ex23-2_wizepharma.htm">Consent of Fahn Kanne &amp; Co. Grant Thornton Israel*</A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">24.1</TD>
      <TD STYLE="text-align: left">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="fs80418ex23-2_wizepharma.htm">Powers of Attorney (included in the signature page to this Registration Statement)</A></TD></TR>
  </TABLE>
  
  
  <P STYLE="margin: 0">___________</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in">* Filed herewith.</P>
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: right"></P>
  
  <!-- Field: Page; Sequence: 9; Options: Last -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">7</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: right"><BR STYLE="clear: both"></P>
  
  </BODY>
  </HTML>
metadata_documents: [{"type": "S-8", "sequence": "1", "filename": "fs80418_wizepharma.htm", "description": "INITIAL REGISTRATION STATEMENT FOR SECURITIES TO BE OFFERED TO EMPLOYEES", "secsgml_size_bytes": 72574}]
metadata_filer: {"company-data": {"conformed-name": "Wize Pharma, Inc.", "cik": "0001218683", "assigned-sic": "2834", "irs-number": "880445167", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-224146", "film-number": "18738215"}, "business-address": {"street1": "5B HANAGAR STREET", "city": "HOD HASHARON", "state": "L3", "zip": "4527708", "phone": "972 472 260 0536"}, "mail-address": {"street1": "5B HANAGAR STREET", "city": "HOD HASHARON", "state": "L3", "zip": "4527708"}, "former-company": [{"former-conformed-name": "OphthaliX, Inc.", "date-changed": "20120207"}, {"former-conformed-name": "DENALI CONCRETE MANAGEMENT INC", "date-changed": "20030213"}]}
text: As filed with the Securities and Exchange Commission on
  April 4, 2018
  Registration No. 333-____
  UNITED STATES
  SECURITIES AND EXCHANGE COMMISSION
  WASHINGTON, D.C. 20549
  _______________
  FORM S-8
  REGISTRATION STATEMENT
  UNDER
  THE
  SECURITIES ACT OF 1933
  _____________
  WIZE PHARMA, INC.
  (Exact name of registrant as specified
  in its charter)
  Delaware
  88-0445167
  (State or Other Jurisdiction of Incorporation
          or Organization)
  (I.R.S. Employer Identification Number)
  5b Hanagar Street, Hod Hasharon, Israel, 4527708
  (Address of Principal Executive Offices; Zip
  Code)
  _______________
  Wize Pharma, Inc. 2018 Stock Incentive Plan
  (Full Title of the Plan)
  _______________
  Or Eisenberg
  Acting CEO and CFO
  Wize Pharma, Inc.
  5b Hanagar Street
  Hod Hasharon, Israel
  4527708
  (Name and Address of Agent for Service)
  +972 (72) 260-0536
  (Telephone Number, Including Area Code, of
  Agent for Service)
  Indicate by check mark whether the registrant
  is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth
  company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting
  company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
  Large accelerated filer
  ☐
  Accelerated filer
  ☐
  Non-accelerated filer
  Smaller reporting company
  ☒
  (Do not check if a smaller reporting
  company)
  ☐
  Emerging growth company
  ☒
  If an emerging growth company, indicate by
  check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
  accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act
  . ☒
  CALCULATION OF REGISTRATION FEE
  Title of Each Class of Securities to be Registered
  Amount
  to be Registered (1)
  Proposed Maximum Offering Price Per Share (2)
  Proposed Maximum Aggregate Offering Price (2)
  Amount of Registration Fee (3)
  Common Stock, $0.001 par value
  435,052
  $
  3.74
  $
  1,627,094.48
  $
  202.57
  (4)
  (1)
  Pursuant
                                           to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"),
                                           there are also being registered hereby an additional indeterminate number of shares of
                                           the Registrant's Common Stock, $0.001 par value (the "Common Stock")
                                           as may become issuable to the selling stockholders as a result of stock splits, stock
                                           dividends and similar transactions, and, in any such event, the number of shares registered
                                           hereby shall be automatically increased to cover the additional share.
  (2)
  The proposed
                                           maximum offering price per share and the proposed maximum aggregate offering price have
                                           been estimated solely for the purpose of calculating the amount of the registration fee
                                           in accordance with Rules 457(c) and 457(h) under the Securities Act, based on the average
                                           of the high and low closing prices of our Common Stock on April 3, 2018, as reported
                                           on the OTCQB, a date within five (5) business days prior to the date of this Registration
                                           Statement.
  (3)
  Determined in accordance with Section 6(b) of the Securities Act at a rate
  equal to $124.50 per $1 million of the proposed maximum aggregate offering price.
  (4)
  The Registration Fee is being offset against a portion of the fee paid by
  the Company upon the filing of a Registration Statement on Form S-1 on February 6, 2018, as a result of the Company's reverse
  stock split of its Common Stock at a ratio of one for twenty-four (1:24) which was effected on March 5, 2018.
  ________________________________
  This Registration Statement shall become effective immediately
  upon filing as provided in Rule 462 under the Securities Act of 1933.
  EXPLANATORY NOTE
  As used in this Registration Statement, the
  terms "we," "us," "our," the "Company," "Wize," "our company"
  and the "Registrant" refer to Wize Pharma, Inc. (formerly known as OphthaliX, Inc.), a Delaware corporation. The references
  to the "Commission" are to the United States Securities and Exchange Commission.
  On February 22, 2018, the Board of Directors
  approved the adoption of the 2018 Stock Incentive Plan (the "2018 Plan"), including the total number of shares of Common
  Stock that may be subject to awards under the 2018 Plan (subject to appropriate adjustments in the case of stock splits, stock
  dividends and similar recapitalization events, the " Reserved Pool"). As of the date hereof, the Reserved Pool is 435,052
  shares of Common Stock.
  The purpose of this Registration Statement on
  Form S-8 is to register 435,052 shares of Common Stock for issuance under the 2018 Plan, all of which are reserved for issuance
  under future stock options, shares of Common Stock, restricted stock and restricted stock units of our company.
  PART I
  INFORMATION REQUIRED
  IN THE SECTION 10(a) PROSPECTUS
  Item 1. Plan Information.
  The Company will provide
  each recipient (the "Recipients") of a grant under the 2018 Plan with documents that contain information related to
  the Plan, and other information including, but not limited to, the disclosure required by Item 1 of Form S-8, which information
  is not required to be and is not being filed as a part of this Registration Statement or as prospectuses or prospectus supplements
  pursuant to Rule 424 under the Securities Act. The foregoing information and the documents incorporated by reference in response
  to Item 3 of Part II of this Registration Statement, taken together, constitute a prospectus that meets the requirements of Section
  10(a) of the Securities Act. A Section 10(a) prospectus will be given to each Recipient who receives common stock covered by this
  Registration Statement, in accordance with Rule 428(b)(1) under the Securities Act.
  Item 2. Registrant Information and Employee
  Plan Annual Information.
  The Company will provide
  to each Recipient a written statement advising of the availability of documents incorporated by reference in Item 3 of Part II
  of this Registration Statement (which documents are incorporated by reference in this Section 10(a) prospectus) and of documents
  required to be delivered pursuant to Rule 428(b) under the Securities Act without charge and upon written or oral request by contacting:
  Or Eisenberg
  Acting Chief Executive
  Officer and Chief Financial Officer
  Wize Pharma, Inc.
  5b Hanagar Street
  Hod Hasharon, Israel
  4527708
  1
  PART II
  INFORMATION REQUIRED IN THE REGISTRATION
  STATEMENT
  Item 3. Incorporation of Documents by Reference.
  Wize hereby incorporates by reference
  into this Registration Statement the following documents previously filed with the Commission:
  (a)
  the Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2017, filed with the Commission on March
  29, 2018;
  (b)
  The description of the Registrant's Common Stock incorporated herein by reference from the Company's Registration
  Statement on Form S-4 filed with the Commission on July 27, 2017, and amended on September 5, 2017, including any amendment or
  report filed for the purpose of updating such description; and
  (c)
  all other reports filed by the Registrant pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended
  (the "Exchange Act"), since the end of the fiscal year covered by the documents referred to in clause (a) above.
  All documents subsequently
  filed by us pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, and all Current Reports on Form 8-K submitted
  to the Commission subsequent to the date hereof, to the extent that such Reports indicate that information therein is incorporated
  by reference into the Registrant's Registration Statements on Form S-8, prior to the filing of a post-effective amendment
  which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be
  deemed to be incorporated by reference in this registration statement and to be part hereof from the date of filing of such documents.
  Any statement contained in a document
  incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this
  Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed
  to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall
  not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
  Item 4.   Description of
  Securities
  .
  Not applicable.
  Item 5.   Interests of Named
  Experts and Counsel
  .
  Not applicable.
  Item 6.   Indemnification
  of Directors and Officers
  .
  As a corporation incorporated in the State
  of Delaware, we are subject to the Delaware General Corporation Law ("DGCL"). Section 102(b)(7) of the DGCL allows
  a corporation to provide in its certificate of incorporation that a director of the corporation will not be personally liable to
  the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except where the director
  breached the duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized
  the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal
  benefit. Our charter provides for this limitation of liability.
  2
  Section 145 of the DGCL ("Section
  145"), provides, among other things, that a Delaware corporation may indemnify any person who was, is or is threatened to
  be made, party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative
  (other than an action by or in the right of such corporation), by reason of the fact that such person is or was an officer, director,
  employee or agent of such corporation or is or was serving at the request of such corporation as a director, officer, employee
  or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys' fees), judgments,
  fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding,
  provided such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the corporation's
  best interests and, with respect to any criminal action or proceeding, had no reasonable cause to believe that his or her conduct
  was unlawful. A Delaware corporation may indemnify any persons who were or are a party to any threatened, pending or completed
  action or suit by or in the right of the corporation by reason of the fact that such person is or was a director, officer, employee
  or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys' fees) actually and
  reasonably incurred by such person in connection with the defense or settlement of such action or suit, provided such person acted
  in good faith and in a manner he or she reasonably believed to be in or not opposed to the corporation's best interests,
  provided further that no indemnification is permitted without judicial approval if the officer, director, employee or agent is
  adjudged to be liable to the corporation. Where an officer or director is successful on the merits or otherwise in the defense
  of any action referred to above, the corporation must indemnify him or her against the expenses (including attorneys' fees)
  which such officer or director has actually and reasonably incurred.
  Section 145 further authorizes a corporation
  to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation
  or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or enterprise,
  against any liability asserted against such person and incurred by such person in any such capacity, or arising out of his or her
  status as such, whether or not the corporation would otherwise have the power to indemnify such person under Section 145.
  Our charter and bylaws provide that we must
  indemnify and advance expenses to its directors and officers to the full extent authorized by the DGCL.
  We expect to maintain standard policies of
  insurance that provide coverage (1) to our directors and officers against loss arising from claims made by reason of breach
  of duty or other wrongful act as defined in the policy and (2) to us with respect to indemnification payments that we may
  make to such directors and officers.
  The indemnification rights set forth above
  shall not be exclusive of any other right which an indemnified person may have or hereafter acquire under any statute, any provision
  of our charter, bylaws, agreement, vote of stockholders or disinterested directors or otherwise. Notwithstanding the foregoing,
  we shall not be obligated to indemnify a director or officer in respect of a proceeding (or part thereof) instituted by such director
  or officer, unless such proceeding (or part thereof) has been authorized by our board of directors pursuant to the applicable procedure
  outlined in our bylaws.
  Section 174 of the DGCL provides, among
  other things, that a director, who willfully or negligently approves of an unlawful payment of dividends or an unlawful stock purchase
  or redemption, may be held jointly and severally liable for such actions. A director who was either absent when the unlawful actions
  were approved or dissented at the time may avoid liability by causing his or her dissent to such actions to be entered in the books
  containing the minutes of the meetings of the board of directors at the time such action occurred or immediately after such absent
  director receives notice of the unlawful acts.
  Item 7.   Exemption from
  Registration Claimed
  .
  Not applicable.
  3
  Item 8. Exhibits.
  The following exhibits
  are filed as part of this registration statement:
  EXHIBIT INDEX
  EXHIBIT NO.
  DESCRIPTION
  3.1
  Certificate of Incorporation (Incorporated by reference to Company's Current Report on Form 8-K filed with the Commission on April 5, 2012)
  3.2
  Certificate of Amendment to Certificate of Incorporation (Incorporated by reference to Company's Current Report on Form 8-K filed with the Commission on July 18, 2013)
  3.3
  Certificate of Amendment to Certificate of Incorporation dated November 15, 2017 (Incorporated by reference to Company's Current Report on Form 8-K filed with the Commission on November 21, 2017)
  3.4
  Certificate of Amendment to Certificate of Incorporation dated March 1, 2018 (Incorporated by reference to Company's Current Report on Form 8-K filed with the Commission on March 5, 2018)
  3.5
  Bylaws (Incorporated by reference to Company's Current Report on Form 8-K filed with the Commission on May 10, 2013)
  4.1
  Specimen Common Stock Certificate (Incorporated by reference to Company's Registration Statement on Form S-1 filed with the Commission on February 6, 2018)
  4.2
  Wize Pharma, Inc. 2018 Equity Incentive Plan (Incorporated by reference to Company's Current Report on Form 8-K filed with the Commission on February 28, 2018)
  5.1
  Opinion of Sichenzia Ross Ference Kesner LLP*
  23.1
  Consent of Sichenzia Ross Ference Kesner LLP (contained in Exhibit 5.1)
  23.2
  Consent of Fahn Kanne & Co. Grant Thornton Israel*
  24.1
  Powers of Attorney (included in the signature page to this Registration Statement)
  ___________
  * Filed herewith.
  4
  Item 9. Undertakings.
  The undersigned Registrant hereby undertakes:
  (1) To file, during any period in which offers or sales are
  being made, a post-effective amendment to this Registration Statement:
  i. To include any prospectus required by
  section 10(a)(3) of the Securities Act of 1933;
  ii. To reflect in the prospectus any facts or
  events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which,
  individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding
  the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would
  not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be
  reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume
  and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the "Calculation
  of Registration Fee" table in the effective Registration Statement;
  iii. To include any material information
  with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such
  information in the Registration Statement;
  provided, however
  , that paragraphs (1)(i)
  and (1)(ii) of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs
  is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or 15(d) of the Exchange
  Act that are incorporated by reference in the Registration Statement.
  (2) That, for the purpose of determining any liability under the
  Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities
  offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
  (3) To remove from registration by means of a post-effective
  amendment any of the securities being registered which remain unsold at the termination of the offering.
  (4) The undersigned Registrant hereby undertakes that, for
  purposes of determining any liability under the Securities Act, each filing of the registrant's annual report pursuant to
  Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report
  pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed
  to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time
  shall be deemed to be the initial bona fide offering thereof.
  (5) Insofar as indemnification for liabilities arising under
  the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing
  provisions, or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification is against
  public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification
  against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling
  person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or
  controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel
  the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification
  by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
  5
  SIGNATURES
  Pursuant to the
  requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all
  of the requirements for filing on Form S-8 and has duly caused this registration statement on Form S-8 to be signed on its behalf
  by the undersigned, thereunto duly authorized, in the City of Hod Hasharon, Israel, on the 4
  th
  day of April, 2018.
  WIZE PHARMA, INC.
  By:
  /s/ Or Eisenberg
  Name:
  Title:
  Or Eisenberg
  Acting Chief Executive Officer, Chief Financial Officer, Treasurer and Secretary
  POWER OF ATTORNEY
  Each of the undersigned officers and directors
  of Wize Pharma, Inc., a Delaware corporation, hereby constitutes and appoints Or Eisenberg and Noam Danenberg and each of them,
  severally, as his or her attorney-in-fact and agent, with full power of substitution and resubstitution, in his or her name and
  on his or her behalf, to sign in any and all capacities this registration statement and any and all amendments (including post-effective
  amendments) and exhibits to this registration statement and any and all applications and other documents relating thereto, with
  the Securities and Exchange Commission, with full power and authority to perform and do any and all acts and things whatsoever
  which any such attorney or substitute may deem necessary or advisable to be performed or done in connection with any or all of
  the above described matters, as fully as each of the undersigned could do if personally present and acting, hereby ratifying and
  approving all acts of any such attorney or substitute.
  Pursuant to the requirements
  of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the
  dates indicated.
  Signature
  Title
  Date
  /s/ Or Eisenberg
  Acting Chief Executive Officer, Chief Financial Officer, Treasurer and Secretary
  April 4, 2018
  Or Eisenberg
  /s/ Ron Mayron
  Chairman of the Board
  April 4, 2018
  Ron Mayron
  /s/ Yossi Keret
  Director
  April 4, 2018
  Yossi Keret
  /s/ Franck Amouyal
  Director
  April 4, 2018
  Franck Amouyal
  /s/ Joseph Zarzewsky
  Director
  April 4, 2018
  Joseph Zarzewsky
  /s/ Michael Belkin
  Director
  April 4, 2018
  Michael Belkin
  6
  EXHIBIT INDEX
  EXHIBIT NO.
  DESCRIPTION
  3.1
  Certificate of Incorporation (Incorporated by reference to Company's Current Report on Form 8-K filed with the Commission on April 5, 2012)
  3.2
  Certificate of Amendment to Certificate of Incorporation (Incorporated by reference to Company's Current Report on Form 8-K filed with the Commission on July 18, 2013)
  3.3
  Certificate of Amendment to Certificate of Incorporation dated November 15, 2017 (Incorporated by reference to Company's Current Report on Form 8-K filed with the Commission on November 21, 2017)
  3.4
  Certificate of Amendment to Certificate of Incorporation dated March 1, 2018 (Incorporated by reference to Company's Current Report on Form 8-K filed with the Commission on March 5, 2018)
  3.5
  Bylaws (Incorporated by reference to Company's Current Report on Form 8-K filed with the Commission on May 10, 2013)
  4.1
  Specimen Common Stock Certificate (Incorporated by reference to Company's Registration Statement on Form S-1 filed with the Commission on February 6, 2018)
  4.2
  Wize Pharma, Inc. 2018 Equity Incentive Plan (Incorporated by reference to Company's Current Report on Form 8-K filed with the Commission on February 28, 2018)
  5.1
  Opinion of Sichenzia Ross Ference Kesner LLP*
  23.1
  Consent of Sichenzia Ross Ference Kesner LLP (contained in Exhibit 5.1)
  23.2
  Consent of Fahn Kanne & Co. Grant Thornton Israel*
  24.1
  Powers of Attorney (included in the signature page to this Registration Statement)
  ___________
  * Filed herewith.
  7